Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-line Treatment of MCapOX in Combination with Cetuximab Versus MFOLFOX6 in Combination with Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided Metastatic Colorectal Cancer: a Multicenter, Randomized, Controlled, Phase III Study

NCT06616259 is registered in ClinicalTrials.gov with Meng Qiu as lead sponsor.

NCT NCT06616259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06616259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-line Treatment of MCapOX in Combination with Cetuximab Versus MFOLFOX6 in Combination with Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided Metastatic Colorectal Cancer: a Multicenter, Randomized, Controlled, Phase III Study
Lead sponsor
Meng Qiu
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 26, 2024
Completion date
September 30, 2029
Enrollment
452 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

capecitabine, cetuximab, colorectal cancer (crc)